大葉大學圖書館 |

New approaches to drug discovery[electronic resource] /

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
杜威分類號:	615.1072
書名/作者:	New approaches to drug discovery/ edited by Ulrich Nielsch, Ulrike Fuhrmann, Stefan Jaroch.
其他作者:	Nielsch, Ulrich.
出版者:	Cham : : Springer International Publishing :, 2016.
面頁冊數:	viii, 341 p. : : ill., digital ;; 24 cm.
Contained By:	Springer eBooks
標題:	Drug development.
標題:	Pharmacology.
標題:	Pharmacy - Research.
標題:	Clinical biochemistry.
標題:	Biomedicine.
標題:	Pharmacology/Toxicology.
標題:	Drug Safety and Pharmacovigilance.
標題:	Medical Biochemistry.
標題:	Metabolomics.
ISBN:	9783319289144
ISBN:	9783319289120
內容註:	Preface -- Part 1. Historical View -- Drug discovery in the past and today.Part 2. Target Discovery -- Emerging target families: intractable targets. In vivo target validation especially for biological targets. HR RNAi/High Content analysis -- Part 3. Lead generation and Optimization -- Sources for leads: natural products, libraries. Screening: assays, readout, technology. Impact of structural biology, fragment based screening/Virtual screening. Predictive in silico tools of compound properties. High throughput synthesis. New compound classes: Protein-Protein Interaction. Sources for biological leads/Screening of biologicals -- Part 4. Test systems for Efficacy and Safety -- In vitro / Cell based assays. Pharmacodynamic. Pharmacokinetic. Safety and toxicology. Impact of biomarkers/personalized medicine. Simulating in vivo drug effects.
摘要、提要註:	This volume gives an overview of state of the art technologies and future developments in the field of preclinical pharmaceutical research. A balanced mix of experts from academia and industry give insight in selected new developments in the drug discovery pathway. The topics cover the different parts of the drug discovery process, starting with new developments in the target identification and validation area. The lead generation part as a next step focuses on the requirements and technologies to identify new small molecules as lead compounds for further optimization; in a second section the technologies to identify biologics as leads are addressed. The final part focuses on the pharmacological models and technologies to characterize new compounds and the impact of biomarkers to facilitate the transfer of drug candidates into the development phase.
電子資源:	http://dx.doi.org/10.1007/978-3-319-28914-4

New approaches to drug discovery[electronic resource] /
New approaches to drug discovery[electronic resource] /edited by Ulrich Nielsch, Ulrike Fuhrmann, Stefan Jaroch. - Cham :Springer International Publishing :2016. - viii, 341 p. :ill., digital ;24 cm. - Handbook of experimental pharmacology,v.2320171-2004 ;. - Handbook of experimental pharmacology ;208..

Preface -- Part 1. Historical View -- Drug discovery in the past and today.Part 2. Target Discovery -- Emerging target families: intractable targets. In vivo target validation especially for biological targets. HR RNAi/High Content analysis -- Part 3. Lead generation and Optimization -- Sources for leads: natural products, libraries. Screening: assays, readout, technology. Impact of structural biology, fragment based screening/Virtual screening. Predictive in silico tools of compound properties. High throughput synthesis. New compound classes: Protein-Protein Interaction. Sources for biological leads/Screening of biologicals -- Part 4. Test systems for Efficacy and Safety -- In vitro / Cell based assays. Pharmacodynamic. Pharmacokinetic. Safety and toxicology. Impact of biomarkers/personalized medicine. Simulating in vivo drug effects.

This volume gives an overview of state of the art technologies and future developments in the field of preclinical pharmaceutical research. A balanced mix of experts from academia and industry give insight in selected new developments in the drug discovery pathway. The topics cover the different parts of the drug discovery process, starting with new developments in the target identification and validation area. The lead generation part as a next step focuses on the requirements and technologies to identify new small molecules as lead compounds for further optimization; in a second section the technologies to identify biologics as leads are addressed. The final part focuses on the pharmacological models and technologies to characterize new compounds and the impact of biomarkers to facilitate the transfer of drug candidates into the development phase.

ISBN: 9783319289144

Standard No.: 10.1007/978-3-319-28914-4doiSubjects--Topical Terms:

339189
Drug development.

LC Class. No.: RM301.25

Dewey Class. No.: 615.1072

New approaches to drug discovery[electronic resource] /
LDR:02742nam a2200325 a 4500 001 446446
003 DE-He213
005 20160909092617.0
006 m d
007 cr nn 008maaau
008 161201s2016 gw s 0 eng d
020 $a 9783319289144 $q (electronic bk.)
020 $a 9783319289120 $q (paper)
024 7 $a 10.1007/978-3-319-28914-4 $2 doi
035 $a 978-3-319-28914-4
040 $a GP $c GP
041 0 $a eng
050 4 $a RM301.25
072 7 $a MMG $2 bicssc
072 7 $a MED071000 $2 bisacsh
082 0 4 $a 615.1072 $2 23
090 $a RM301.25 $b .N532 2016
245 0 0 $a New approaches to drug discovery $h [electronic resource] / $c edited by Ulrich Nielsch, Ulrike Fuhrmann, Stefan Jaroch.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2016.
300 $a viii, 341 p. : $b ill., digital ; $c 24 cm.
490 1 $a Handbook of experimental pharmacology, $x 0171-2004 ; $v v.232
505 0 $a Preface -- Part 1. Historical View -- Drug discovery in the past and today.Part 2. Target Discovery -- Emerging target families: intractable targets. In vivo target validation especially for biological targets. HR RNAi/High Content analysis -- Part 3. Lead generation and Optimization -- Sources for leads: natural products, libraries. Screening: assays, readout, technology. Impact of structural biology, fragment based screening/Virtual screening. Predictive in silico tools of compound properties. High throughput synthesis. New compound classes: Protein-Protein Interaction. Sources for biological leads/Screening of biologicals -- Part 4. Test systems for Efficacy and Safety -- In vitro / Cell based assays. Pharmacodynamic. Pharmacokinetic. Safety and toxicology. Impact of biomarkers/personalized medicine. Simulating in vivo drug effects.
520 $a This volume gives an overview of state of the art technologies and future developments in the field of preclinical pharmaceutical research. A balanced mix of experts from academia and industry give insight in selected new developments in the drug discovery pathway. The topics cover the different parts of the drug discovery process, starting with new developments in the target identification and validation area. The lead generation part as a next step focuses on the requirements and technologies to identify new small molecules as lead compounds for further optimization; in a second section the technologies to identify biologics as leads are addressed. The final part focuses on the pharmacological models and technologies to characterize new compounds and the impact of biomarkers to facilitate the transfer of drug candidates into the development phase.
650 0 $a Drug development. $3 339189
650 0 $a Pharmacology. $3 213245
650 0 $a Pharmacy $x Research. $3 617699
650 0 $a Clinical biochemistry. $3 366859
650 1 4 $a Biomedicine. $3 463454
650 2 4 $a Pharmacology/Toxicology. $3 463455
650 2 4 $a Drug Safety and Pharmacovigilance. $3 604911
650 2 4 $a Medical Biochemistry. $3 463462
650 2 4 $a Metabolomics. $3 465184
700 1 $a Nielsch, Ulrich. $3 639103
700 1 $a Fuhrmann, Ulrike. $3 639104
700 1 $a Jaroch, Stefan. $3 639105
710 2 $a SpringerLink (Online service) $3 463450
773 0 $t Springer eBooks
830 0 $a Handbook of experimental pharmacology ; $v 208. $3 466630
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-28914-4
950 $a Biomedical and Life Sciences (Springer-11642)